Safety and Feasibility of the XFLO Expander System (Mercury)

Inclusion Criteria: * Male gender * Age ≥ 50 years * Prostate volume 30 - 80 cc by Abdominal Ultrasound (AUS) or Trans Rectal Ultrasound (TRUS) * Prostatic urethra length of 2.0-6.0 cm, as measured from bladder neck to verumontanum, using cystoscopy (or prostate length from bladder neck to external sphincter of 2.0-8.0 cm during screening visit, using ultrasound). * Medication history * Not on BPH related medication for the past 6 months. * If on BPH related medication: * On 5-alpha-reductase inhibitors (ARIs), the patient must be on the medication for at least 3 months with a stable voiding pattern * On alpha-blockers, the patient must be on the medication for at least 3 weeks with a stable voiding pattern * Patients with symptomatic BPH and related lower urinary tract symptoms (LUTS): * With International Prostate Symptom Score (IPSS) \> 13; Qmax \< 12 mL/sec on a voided volume ≥125 mL; Post-void residual (PVR) \< 250 mL; QoL score ≥ 3 Exclusion Criteria: * Previous BPH procedure * Median prostatic lobe or high bladder neck * Urethral stricture, meatal stenosis, or bladder neck obstruction - either current, or recurrent requiring 2 or more dilatations * Elevated Prostate Specific Antigen (PSA) ≥ 10 ng/mL unless negative biopsy within last 6 months, or a positive biopsy showing cancer * Cystolithiasis within the prior 3 months * History of neurogenic bladder or urinary retention with PVR \>1000mL. * Serum creatinine \>1.8 mg/dl or upper-tract disease which compromises renal function * Current or recent Urinary Tract Infection (UTI) or disease * Known allergy to nickel * Life expectancy of less than 24 months * Known coagulopathies or subject on anticoagulants or antiplatelets other than aspirin ≤ 100 mg (unless antiplatelets are withheld minimum 3 days prior to procedure) * Anticipated need for additional surgery or treatments for comorbidities during the study period. * Current gross hematuria * Other co-morbidities that could impact the study results * Unable or unwilling to complete all required questionnaires and follow-up assessments * Unable or unwilling to sign informed consent form * Currently enrolled in any other investigational clinical research trial that has not completed the primary endpoint.